Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8381122 | 0.96 | CA1 (0.53) | TDP1CA1CA2SIGMAR1GAA | |
| SCHEMBL31307112 | 0.87 | TDP1 (0.54) | TDP1CA1CA2SIGMAR1GAA | |
| SCHEMBL31307113 | 0.87 | TDP1 (0.58) | TDP1CA1CA2SIGMAR1GAA | |
| SCHEMBL917871 | 0.87 | TDP1 (0.54) | TDP1CA1CA2SIGMAR1GAA | |
| SCHEMBL21482939 | 0.86 | TDP1 (0.53) | TDP1CA1CA2SIGMAR1GAA | |
| SCHEMBL938186 | 0.86 | CA1 (0.55) | TDP1CA1CA2SIGMAR1GAA | |
| SCHEMBL7272921 | 0.86 | TDP1 (0.56) | TDP1CA1CA2SIGMAR1GAA | |
| SCHEMBL4961185 | 0.85 | SIGMAR1 (0.62) | TDP1SIGMAR1GAAPOLBNPSR1 | |
| SCHEMBL2328583 | 0.84 | TDP1 (0.51) | TDP1CA1CA2SIGMAR1GAA | |
| SCHEMBL16264885 | 0.84 | TDP1 (0.55) | TDP1CA1CA2SIGMAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022210-B2 | 3-Aminopyrazine-2-carbonylguanidine derivatives; (4-{4-[N'-(3,5-Diamino-6-chloropyrazine-2-carbonyl)guanidino]butyl}phenoxy)acetic acid 2-piperidin-1-yl-ethyl ester; hydration of mucous membranes; respiratory system and gastrointestinal disorders; skin, eye and vaginal dryness; hypotensive agents; asthma | PARION SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022210-B2 | 3-Aminopyrazine-2-carbonylguanidine derivatives; (4-{4-[N'-(3,5-Diamino-6-chloropyrazine-2-carbonyl)guanidino]butyl}phenoxy)acetic acid 2-piperidin-1-yl-ethyl ester; hydration of mucous membranes; respiratory system and gastrointestinal disorders; skin, eye and vaginal dryness; hypotensive agents; asthma | PARION SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8008494-B2 | 2-(4-{4-[N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidino]-butyl}phenoxy)-N-(3-dimethylaminopropyl)acetamide dimethanesulfonate; promoting hydration of mucosal surfaces; Sjogren's disease, esophagitis, pneumonia, asthma, otitis, constipation, chronic diverticulitis, rhinosinusitis | PARION SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008494-B2 | 2-(4-{4-[N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidino]-butyl}phenoxy)-N-(3-dimethylaminopropyl)acetamide dimethanesulfonate; promoting hydration of mucosal surfaces; Sjogren's disease, esophagitis, pneumonia, asthma, otitis, constipation, chronic diverticulitis, rhinosinusitis | PARION SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7875619-B2 | N-[4-(4-{2-[bis-((2S,3R)-2,3,4-trihydroxybutyl)amino]ethylamino}phenyl)butyl]-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine trihydrochloride; treating chronic bronchitis, cystic fibrosis, ventilator-induced pneumonia, asthma, chronic obstructive pulmonary disease, pneumonia and emphysema | PARION SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875619-B2 | N-[4-(4-{2-[bis-((2S,3R)-2,3,4-trihydroxybutyl)amino]ethylamino}phenyl)butyl]-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine trihydrochloride; treating chronic bronchitis, cystic fibrosis, ventilator-induced pneumonia, asthma, chronic obstructive pulmonary disease, pneumonia and emphysema | PARION SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7842697-B2 | Soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842697-B2 | Soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090324724-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324724-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7399766-B2 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1924263-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS WITH SOLUBLE AMIDE AND ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008030217-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS WITH SOLUBLE AMIDE AND ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060142581-A1 | Hetero substitued sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| EP-1599096-A4 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-02-23 | — | — | US | disclosed |
| EP-1599096-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004073629-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142581-A1 | Hetero substitued sodium channel blockers | SCN2B, CACNA1B, CACNA1G | TDP1 4269/4885CA1 2788/4885CA2 329/4885 |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | SCN2A, CACNA1B, HCN4 | TDP1 4353/4885CA1 1101/4885CA2 187/4885 |
| US-20090324724-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCN2A, CACNA1B, HCN4 | TDP1 4353/4885CA1 1101/4885CA2 187/4885 |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | KCNN2, KCNN1, KCNN3 | TDP1 4255/4885CA1 1402/4885CA2 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.